Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Appointed director

Jaguar Health, Inc. (JAGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series I Convertible Preferred Stock",
"Global Amendment No. 2, by and between Jaguar Health, Inc. and Iliad Research and Trading, L.P",
"Global Amendment No. 2, by and between Jaguar Health, Inc. and Uptown Capital, LLC",
"Global Amendment, by and between Jaguar Health, Inc. and Streeterville Capital, LLC",
"Global Amendment No. 2, by and between Jaguar Health, Inc. and Streeterville Capital, LLC",
"Form of Warrant",
"Exchange Agreement, by and between Jaguar Health, Inc. and Uptown Capital, LLC"
08/14/2023 8-K Quarterly results
Docs: "Jaguar Health Reports Second Quarter 2023 Financial Results"
07/07/2023 8-K Quarterly results
07/03/2023 8-K Quarterly results
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Second Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan",
"Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635"
05/15/2023 8-K Quarterly results
Docs: "Jaguar Health Reports First Quarter 2023 Financial Results"
05/12/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/09/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock",
"Form of Warrant",
"Form of Securities Purchase Agreement",
"Standstill Agreement",
"Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea"
03/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
02/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Jaguar Health Regains Compliance with Nasdaq’ s Bid Price Requirement"
02/06/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financi...
Docs: "MUTUAL TERMINATION OF LICENSE AGREEMENT",
"Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’ s 2023 Focus on Human Drug Development"
01/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/30/2022 8-K Quarterly results
11/16/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
10/14/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDED AND RESTATED license AND SERVICES AGREEMENT"
09/30/2022 8-K Quarterly results
08/30/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "ROYALTY INTEREST",
"NOW, THEREFORE, in consideration of the above recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company and Investor hereby agree as follows: 1. Purchase and Sale of Interest . 1.1. Purchase of Interest . Company shall issue and sell to Investor and Investor agrees to purchase from Company the Interest. In consideration thereof, Investor shall pay $4,000,000.00 to Company at the Closing . 1.2. Form of Payment . On the Closing Date , Investor shall pay the Purchase Price to Company via wire transfer of immediately available funds against delivery of the Interest. 1.3. Closing Date . The closing of the transactions contemplated by this Agreement shall occur on August 24, 2022 so long as all of the conditions set forth in Section...",
"Transaction proceeds will be allocated to support the company's ongoing OnTarget pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted cancer therapy SAN FRANCISCO, CA / ACCESSWIRE / August 25, 2022 /"
08/23/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "TERMS OF Series E PREFERRED STOCK",
"Schedule of Purchasers",
"FIRST AMENDMENT TO LICENSE AND SERVICES AGREEMENT"
08/19/2022 8-K Quarterly results
08/18/2022 8-K Quarterly results
07/26/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
07/20/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "GLOBAL AMENDMENT",
"GLOBAL AMENDMENT",
"GLOBAL AMENDMENT",
"GLOBAL AMENDMENT",
"Jaguar Health, INC. First AMENDMENT TO 2020 New Employee Inducement Award PLAN"
04/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/18/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "First AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF Jaguar Health, INC."
03/15/2022 8-K Unregistered Sales of Equity Securities  Interactive Data
03/11/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Jaguar Health Provides Company Updates and Reports 2021 Financials"
03/02/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy